Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients

• Published in: Journal of translational medicine 2021-06, Vol.19 (1), p.1-265, Article 265
• Main Authors: Haderbache, Rafik, Warda, Walid, Hervouet, Eric, da Rocha, Mathieu Neto, Trad, Rim, Allain, Vincent, Nicod, Clementine, Thieblemeont, Catherine, Boissel, Nicolas, Varlet, Pauline, Agha, Ibrahim Yakoub, Bouquet, Lucie, Guiot, Melanie, Venet, Fabienne, Sujobert, Pierre, Roussel, Xavier, Rouzaire, Paul-Oliver, Caillot, Denis, Casasnovas, Olivier, Bories, Jean Christophe, Bachy, Emmanuel, Caillat-Zucman, Sophie, Deschamps, Marina, Ferrand, Christophe
• Format: Article
• Language: English
• Subjects: Acute lymphoblastic leukemia; Acute myeloid leukemia; Animal models; Antigen receptors, T cell; Axi-cel; B-cell lymphoma; Bone marrow; Cancer; Care and treatment; CD19 antigen; Cell culture; Chimeric antigen receptor; Chimeric antigen receptors; Clinical trials; Cloning; Copy number; Droplet digital PCR; Drug therapy; Drug utilization; Flow cytometry; Genetic aspects; Genetic engineering; Genetic testing; Growth factors; Hematology; Human health and pathology; IL-1RAP; Immune system; Interleukin 1 receptors; Leukemia; Life Sciences; Lymphatic leukemia; Lymphocytes; Lymphocytes T; Lymphomas; Methodology; Methods; Monitoring; Monoclonal antibodies; Multiple myeloma; Multiplicity of infection; Myeloid leukemia; Patients; Polymerase chain reaction; Proteins; Receptors; Spleen; T cells; Tisa-cel; Xenografts
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-021-02925-z

Background Genetically engineered chimeric antigen receptor (CAR) T lymphocytes are promising therapeutic tools for cancer. Four CAR T cell drugs, including tisagenlecleucel (tisa-cel) and axicabtagene-ciloleucel (axi-cel), all targeting CD19, are currently approved for treating B cell malignancies. Flow cytometry (FC) remains the standard for monitoring CAR T cells using a recombinant biotinylated target protein. Nevertheless, there is a need for additional tools, and the challenge is to develop an easy, relevant, highly sensitive, reproducible, and inexpensive detection method. Molecular tools can meet this need to specifically monitor long-term persistent CAR T cells. Methods Based on 2 experimental CAR T cell constructs, IL-1RAP and CS1, we designed 2 quantitative digital droplet (ddPCR) PCR assays. By targeting the 4.1BB/CD3z (28BBz) or 28/CD3z (28z) junction area, we demonstrated that PCR assays can be applied to approved CD19 CAR T drugs. Both 28z and 28BBz ddPCR assays allow determination of the average vector copy number (VCN) per cell. We confirmed that the VCN is dependent on the multiplicity of infection and verified that the VCN of our experimental or GMP-like IL-1RAP CAR T cells met the requirement (< 5 VCN/cell) for delivery to the clinical department, similar to approved axi-cel or tisa-cel drugs. Results 28BBz and 28z ddPCR assays applied to 2 tumoral (acute myeloid leukemia (AML) or multiple myeloma (MM) xenograft humanized NSG mouse models allowed us to quantify the early expansion (up to day 30) of CAR T cells after injection. Interestingly, following initial expansion, when circulating CAR T cells were challenged with the tumor, we noted a second expansion phase. Investigation of the bone marrow, spleen and lung showed that CAR T cells disseminated more within these tissues in mice previously injected with leukemic cell lines. Finally, circulating CAR T cell ddPCR monitoring of R/R acute lymphoid leukemia or diffuse large B cell lymphoma (n = 10 for tisa-cel and n = 7 for axi-cel) patients treated with both approved CAR T cells allowed detection of early expansion, which was highly correlated with FC, as well as long-term persistence (up to 450 days), while FC failed to detect these events. Conclusion Overall, we designed and validated 2 ddPCR assays allowing routine or preclinical monitoring of early- and long-term circulating approved or experimental CAR T cells, including our own IL-1RAP CAR T cells, which will be evaluated in an up